Roan Capital Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$272K Buy
235
+39
+20% +$46K 0.2% 65
2026
Q2
$235K Sell
196
-38
-16% -$38.8K 0.2% 72
2026
Q1
$215K Buy
+234
New +$237K 0.2% 71

Other funds holding LLY

Roan Capital Partners's LLY Position: Q3 2026 in Review

Roan Capital Partners increased its Eli Lilly (LLY) stake by 20% in Q3 2026, buying an estimated $46K and bringing the position to 235 shares worth $272K. The position accounts for 0.2% of the portfolio, ranked #65.

Roan Capital Partners first reported a position in LLY in Q1 2026 and has held it in 3 quarters since. 4,631 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Roan Capital Partners held 235 shares of Eli Lilly worth $272K as of Q3 2026.
  • Roan Capital Partners bought 39 Eli Lilly shares in Q3 2026, an estimated $46K.
  • Eli Lilly made up 0.2% of Roan Capital Partners's portfolio in Q3 2026, its #65 holding.
  • Roan Capital Partners first reported a position in Eli Lilly in Q1 2026 and has held it in 3 quarters since.
  • 4,631 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Roan Capital Partners's 13F filing for Q3 2026, filed 9 Oct 2026.